CD19 and B-cell non-Hodgkin lymphoma: Here, we present data from two discontinued phase 1 studies that evaluated the safety, pharmacokinetics (PK) and activity of AFM11 in patients with R/R CD19-positive B cell NHL (AFM11-101 [NCT02106091]) and in patients with CD19 + B-precursor Philadelphia-chromosome negative ALL (AFM11-102 [NCT02848911]).